Synthesis and Characterization of a Novel Drug Delivery System Based on Immunoglobulin G Nanoparticles and Study of Oxaliplatin Release

Document Type : Research Article


Biomaterial Group, Nanotechnology and Advanced Materials Department, Materials and Energy Research Center, Karaj, I.R. IRAN


Synthesis of stable drug carriers for drug delivery based on immunoglobulin G (IgG) in the release of oxaliplatin as an anticancer drug was carried out and characterized infrared spectroscopy (FT-IR) and Scanning Electron Microscopy (SEM). In this paper, the drug release tests were performed for pure IgG and two different ratios of drug / IgG nanoparticles (IgG-NPs) (1:1 and 2:1). Drug loading and encapsulation were determined for three systems. The results showed that the drug release was sustained in IgG NPs systems in comparison with pure IgG. Also, the release mechanism was studied and indicated that the mechanism was fickian diffusion. Therefore, the designed system is a suitable candidate for drug release of anticancer drugs.


Main Subjects

 [1] Pathak Y., Recent Developments in Nanoparticulate Drug Delivery Systems, Drug Delivery Nanoparticles Formulation and Characterization, 2016: 19-33 (2016).‏
[2] Lohcharoenkal W., Wang L., Chen Y.-C., Rojanasaku Y., Protein Nanoparticles as Drug Delivery Carriers for Cancer Therapy, Biomed Research International, 2014: 1-12 (2014).‏
[3] Soppimath K.-S., Aminabhavi T.-J., Kulkarni A.-R., Rudzinsli W.-E., Biodegradable Polymeric Nanoparticles as Drug Delivery Devices, Journal of Controlled Release, 70: 1-20 (2001).‏
[4] Salatin S., Jelvehgari M., Maleki-Dizaj S., Adibkia K., A Sight on Protein-Based Nanoparticles as Drug/Gene Delivery Systems, Therapeutic Delivery, 6: 1017-1029 (2015).‏
[5] Dobrovolskaia M.-A., Scott E.-M., Immunological Properties of Engineered Nanomaterials, Nature nanotechnology, 2: 469-478 (2007).
[6] Saif M.-W., Reardon J., Management of Oxaliplatin-Induced Peripheral Neuropathy, Therapeutics and Clinical Risk Management, 1: 249–258 (2005).‏
[7] Peer D., Karp J., Hong S., Farokhzad O., Margalit R., Langer R., Nanocarriers as an Emerging Platform for Cancer Therapy, Nature Nanotechnology, 2: 751-760 (2007).‏
[8] Rezaee F., Saeidifar M., Javaheri M., Sangpour P., Prolonged Release Evaluation of an Injectable Anticancer Drug using Human Serum Albumin Nanoparticle, Biomacromolecular Journal, 2: 118-125 (2016).
[9] نبی تیر معصومه؛ آقامیری سید فواد؛ طلایی خوزانی محمدرضا؛بررسی آزمایشگاهی تأثیر پوشش دهی کیتوسان در کاهش تجمع نانولوله های کربنی به عنوان حامل داروی ضد سرطان کوئرستین، نشریه شیمی و مهندسی شیمی ایران، 36: 93 تا 102 (1396).
[10] Ma P., Mumper R.-J., Paclitaxel Nano-Delivery Systems: A Comprehensive Review, Journal of Nanomedicine & Nanotechnology, 18: 1000164 (2013).‏
[11] Amr Selim Abu L., Kiwada H., Ishida T., Selective Delivery of Oxaliplatin to Tumor Tissue by Nanocarrier System Enhances Overall Therapeutic Efficacy of the Encapsulated Oxaliplatin, Biological and Pharmaceutical Bulletin, 37: 206-211 (2014).‏
[12] Nemati Kharat A., Tamaddoni Jahromi B., Mohammadifar E., Zareyi J., Synthesis of Cis-Diammine (1,1-cyclobutane dicarboxylate) Platinum(II), Iranian Journal of Chemistry and Chemical Engineering, 36: 39-43 (2017).‏
[13] Pathak Y., Benita S., "Antibody-mediated Drug Delivery Systems: Concepts, Technology, and Applications", John Wiley & Sons, (2012).‏
[14] Janeway Jr., Charles A., Travers P., Walport M., "The Structure of a Typical Antibody Molecule", Garland Science, New York (2001).‏
[15] Wong H.-M., Wang J.-J., Wang C.-H., In Vitro Sustained Release of Human Immunoglobulin G from Biodegradable Microspheres, Industrial & Engineering Chemistry Research. 40: 933-948 (2001).‏
[16] Wang J., Chua K.-M., Wang C.-H., Stabilization and Encapsulation of Human Immunoglobulin G Into Biodegradable Microspheres, Journal of Colloid And Interface Science, 271: 92-101 (2004).‏
[17] Marquette S., Peerboom C., Yates A., Denis L., Langer I., Amighi K., Goole J., Stability Study of Full-Length Antibody (anti-TNF alpha) Loaded PLGA Microspheres, International Journal of Pharmaceutics, 470: 41-50 (2014).‏
[18] Elzoghby A.-O., Wael M.-S., Nazik A.-E., Albumin-Based Nanoparticles as Potential Controlled Release Drug Delivery Systems, Journal of Controlled Release, 157: 168-182 (2012).‏
[19] Abbasi S., Arghya P., Prakash S., Investigation of siRNA-loaded Polyethylenimine-Coated Human Serum Albumin Nanoparticle Complexes for the Treatment of Breast Cancer, Cell Biochemistry and Biophysics, 61: 277-287 (2011).‏
[20] Sebak S., Mirzaei M., Malhotra M., Kulamarva A., Prakash S., Human Serum Albumin Nanoparticles as an Efficient Noscapine Drug Delivery System for Potential use in Breast Cancer: Preparation and in Vitro Analysis, International Journal of Nanomedicine, 5: 525-532 (2010).‏
[21] Langer K., Anhorn M., Steinhauser I., Dreis S., Celebi D., Schrickel N., Faust S., Vogel V., Human Serum Albumin (HSA) Nanoparticles: Reproducibility of Preparation Process and Kinetics of Enzymatic Degradation, International Journal of Pharmaceutics, 347: 109-117 (2008).‏
[22] Jahanban.-E A., Dastmalchi S., Davaran S., A simple Improved Desolvation Method for the Rapid Preparation of Albumin Nanoparticles, International Journal of Biological Macromolecules, 91: 703-709 (2016).‏
[23] Guven A., Rusakova I.-A., Lewis M.-T., Wilson L.-J., Cisplatin@ US-Tube Carbon Nanocapsules for Enhanced Chemotherapeutic Delivery, Biomaterials, 33: 1455-1461 (2012).‏
[24]Singhvi G., Singh M., In-vitro Drug Release Characterization Models, International Journal of Pharmaceutical Sciences and Research, 2: 77-84 (2011).‏
[25] Jahanshahi M., Najafpour Gh., Rahimnejad M., Applying the Taguchi Method for Optimized Fabrication of Bovine Serum Albumin (BSA) Nanoparticles as Drug Delivery Vehicles, African Journal of Biotechnology, 7: 362-367 (2008).‏
[26] Suvakanta D., Murthy P.-N., Nath L., Chowdhury P., Kinetic Modeling on Drug Release from Controlled Drug Delivery Systems, Acta Poloniae Pharmaceutica, 67: 217-23 (2010).
[27] Kirubha S.-P., M. Anburajan., Spectrometric Techniques for Diagnosis of Breast Cancer,International Conference on Computer Communication and Informatics, 2: 1-4 (2012).